[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]-[illegible], [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]

[illegible] [illegible] [illegible] [illegible] [illegible]

[illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] '[illegible] [illegible] [illegible]:

* **[illegible] [illegible] [illegible] (Blueprint) [illegible]:**
* [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
* [illegible] [illegible] [illegible] (**MTHFR**) [illegible] [illegible] [illegible] [illegible]
* **COMT** [illegible] **DRD2** [illegible] [illegible] [illegible] [illegible] [illegible]

* **[illegible] [illegible]:**
* [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
* [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible]
* [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

* **[illegible] [illegible]:**
* [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
* [illegible] [illegible] [illegible] [illegible]
* [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

* **[illegible] [illegible] [illegible] [illegible]:**
* **Recovery Kernel** [illegible] [illegible] [illegible]

* **Naloxone** [illegible]

[illegible] **findahelpline.com** '[illegible]

[illegible].

[illegible] — [illegible] **06** [illegible]

[illegible]

[illegible]

[illegible] vulnerabilities [illegible]

[illegible]: [illegible]

[illegible]

□□□-□□□□□ □□□□ □□□□□

□□ □□□□□□□□□□ — □□ □□□□□□□□□□ □□ □□□□□ '□□ □□□□□□□ □□□ □□□□ □□□

□□□□ □□□□□ □□□□□□□ □□□ □□□□ □□□□□□ □□□ □□□□□, □□□□ □□□□ □□ □□□□□□ □□□ □□□□□□□□□□ □□□ □□ □□□□□ □□□□ □□□ □□ □□ □□□□□ □□□□, □□□□□□□□ □□□ □□□□□ □□□□ □□□□□□□ □□ □□□ □□□□□ □□, □□ □□ □□□□□□□□ □□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□□□□ "□□□-□□□□□□ □□□□" □□□□ □□ □□□□ □□□□ □□□□□ □□:

□□□□□ 1 — □□□□ □□□□□□□ □□□ □□□□□	□□□□□ 2 - □□ □□□□□□□ □□ □□ □□□ □□□□□	□□□□□ 3 - □□ □□□□□□ □□□ □□□ □□ □□□□□□□ □□□□□□ □□□□□□□□□□□□ □□□
□□□□□□□ □□□□□□□□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□□□ □□□ □□□□□□□ □□□ □□□□ □□□□□ □□ □□□□ □□ □□□ □□□ □□□□□□□ □□□□□□□□□□ □□□□ □□□□□ □□□ MTHFR □□□□ □□□□□□ □□□ □□□□□□ □□ □□□□□□□□□□ □□□□ □□□□□□ □□□□□ DRD2 A1 □□□□ □□ □□□□□□ □□ □□□□□□ □□□□□□□ □□□ □□□□□ □□□ □□□ □□□□□□ □□ □□□□ □□ □□□ □□□□□□□ □□□ COMT □□□□□□ □□□□□□□ □□□□□ □□ □□□□□□□ □□□□ □□ □□ □□ □□□□□□□ □□□□□ □□□ □□□□□□ □□ □□□□□□ □□□ □□□ □□ □□□□□ □□□□□□ □□ □□□□□□□□□□ □□□	□□□□ □□□□□□ □□□□ □□□□□□□□□, □□□□□□□□□□, □□□□□ □□□□□□□□ □□□ □□□□□□□□□□□ □□□□□□□ □□□□□□ □□□ □□□□□□□□ □□□□□ □□□□ □□□□□□□□, □□□ □□ □□□ □□□ □□□□□□□ □□□□□ □□□□□□□□ □□ □□□□□□□ □□□ □□□□ □□□□□ □□ □□□□ □□□ □□□□□□□□□□ □□ □□□, □□□□□□□ □□□□□□□□□□ □□□ □□□□ □□□□□ □□□□□ □□□ □□, □□□□□□ □□ □□□□□□□ □□ □□□□ □□, □□ □□□ □□□□□□□ □□ □□ □□□□□□□ □□□□□□□□□□ □□ □□□□	□□□□□□□ □□□ □□□□□ □□ □□□□□□□□□ □□□□ □□ □□ □□□ □□□□□□□ □□□□ □□□□□□ □□□□□□□ □□□□ □□□ □□ □□□□□□□□ □□□ □□□ CYP2D6 □□□-□□□□□□□□□□□□□ □□ □□□□□□□ □□□□□ □□, □□ □□□□ □□□□ □□□ □□□ GABRA2 □□□-□□□□ □□□□ □□□□□□□ □□ □□□□□ □□□□□ □□, □□ □□□□ □□□□ □□□ □□□ MTHFR C677T □□□□□□□□□□□ □□ □□□□□ □□□□ □□ □□□□ 5-MTHF □□□□□ □□, □□□□ □□□□□□□□ □□□□□□□ □□ □□□ □□□□ □□ □□□□□□□ □□□□ □□□□□□□□ □□□ □□ □□□□□□□ □□□□□□□□□□□□ □□ □□□ □□□□□ □□□□□ □□□□ □□□□

□□□-□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□ □□□ □□□□ □□□□ □□□□—□□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□ □□□ □□□□□ □□□ □□ □□ □□□□□□, □□□-□□□ □□□□ □□□□□ □□□ □□□□ □□□□ □□ □□ □□□□□□ □□□□□ □□□□□□ □□□□ □□□□□□□ □□ □□□ □□□□ □□□□□ □□: □□□□□□ □□□□, □□□□□ □□□□□□□□□□ □□ □□ □□□ □□□□ MTHFR □□□□ □□□□□ □□ □□□ □□□□□□□ □□ □□□□□ □□, □□□□□ □□□□ □□ SSRIs □□□□□□ □□□□□□□ □□□□, □□ □□□□□ □□□□□□□□ □□ □□□□□□ □□□ ADHD □□ □□ □□□□□□□□□□ □□ □□□ □□□□ □□□□□□□□ □□ □□□ □□□□ □□□□ □□, □□□□□ □□□ DRD2 □□ □□□□□□ □□□□□ □□□□ □□ □□□□ □□□ □□□□ □□□□□ □□□□ □□□□□□ □□ □□ □□□ □□□□ Sage COMT □□□□ □□□□□□ □□□□□□ □□□□□□ □□ □□□□□ □□, □□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□ □□□□□□□ □□ □□□□ □□□ □□ □□ □□□□□□ □□ □□□□□□□ □□□ □□□ □□□-□□□□□□□ □□□□□ □□□□□ □□ □□□□ □□□

□□□□ 1 — □□□□ □□□□□ □□□□□□ □□□ — □□□□□□□ □□□□□

□□ □□□□□□□□□ — □□□□□ □□□□□ □□ □□□ □□□□□, □□□ □□ □□□ □□ □□□

□□ □□□□□□ □□□□□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□ '□□ □□□□□ □□□□ □□□ □□□□□□□□ □□ □□□□□□□ □□□□ □□□ □□□□□□□□ □□□□□ □□□ □□□□ □□□□□ □□ □□□□□□□□□□ □□□□□□□ □□□□□□ □□□□□□ □□□□□ □□□ □□ □□□□ □□□□ □□□ □□ □□ □□□□□□□□ □□ □□□□ '□□ □□□□ □□□□ □□□□ □□□□ □□□□□□ — □□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□ □□□□□ □□□

1.1 — □□□ □□□□□□ □□ □□□□ □□□□□□ □□?

□□□□ □□ □□□□□	□□ □□ □□□□□□ □□□□ □□□	□□ □□□□□□□ □□ □□□□□□□□ □□□□ □□□
30 □□□ □□□□ □□□□□ □□□□□□□□□□ (WGS)□	□□ □□□□□ □□ □□□□ '□□ □□□□ □□□□□□□ □□□□□□ □□ □□□□ SNP (□□□□□ □□□□□□□□□□□ □□□□□□□□), □□□□□□□, □□□□□□□ □□□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□ □□□ □□□□□□□: □□□ VCF (□□□□□□□ □□□ □□□□□□) □□□□ — □□ □□ □□□ □□□□ □□ □□□□□ Python □□□□□□□□□ □□□ □□□ □□□□□ □□□	□□□□□□□□_□□□□_□□□□□_□□□□□□□ □□.py □□□□□□□ □□ □□□□□□□ Nebula Genomics, Dante Labs, Sequencing.com □□□□ 30x WGS □□□□ □□□□ □□□ □□□□ $200–$400 □□□ □□□□ □□ □□ □□□ □□ □□□ □□□ □□ □□□□□□□ □□□□□□ □□□
□□□□□□□ SNP □□□ (23andMe, Ancestry)	□□□□ 700,000 □□□ SNP (□□□□□ □□□□□□□□□□ □□□□□□□□□□) □□ □□□□ □□□□ □□□ □□ □□□ □□□□□□□□□ □□□□ □□□□ □□—□□ □□□□□ □□□□□□ □□□ □□□ □□□□ □□ □□□□□□ '□□ □□ □□□□ □□□□□ □□□ □□□□ □□□□ .txt □□□□ □□□□ □□□□□□□ □□□□ □□ □□□□ □□□ □□□□ □□□□□ MTHFR, COMT, DRD2, □□□ □□ Genetic Genie □□□ Promethease □□□□□ □□□□ □□ □□□□ □□□	□□ □□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□ □□ □□□□ □□□□□□□□□ □□ □□□□□□□ VCF □□□□ □□□□ □□□□□□□□ □□ MTHFR C677T □□□ A1298C, COMT Val158Met, □□□ □□□ CYP □□□□□□□□□ □□□ □□□ □□□□ □□□ □□□□□ □□□ □□□□□□ □□□□ □□□□ □□□□ □□□□ □□□ □□□□□ WGS □□ □□□□ □□□□□ □□□□ □□ □□□□□□ □□□□ □□□ (raw) □□□□ □□□ □□□□□ □□□□□□ □□□ □□ □□□□□ □□□□ □□□□□□□ □□□□
□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□ (GeneSight, Mayo Clinic GeneGuide).	CYP2D6, CYP2C19, CYP3A4, CYP2B6 □□□ □□□ □□□□□□ □□□□□ □□□ □□□□ □□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□ □□□□□ '□□□ □□□□□ □□□□□□□-□□□□ □□ □□□□□ □□□	□□□□□□□□□ □□□□ □□□□□□□ □□ □□□□□ □□ □□□□□ □□□□□□ □□□□□□□□□ (□□□ 5) □□ □□□ □□ □□□□ □□□□□ □□□□□□□□ □□ WGS □□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□ □□□□□ □□□□ □□, □□□ □□□ □□□ □□□ □□□ □□ □□□□□ WGS □□□ □□□□□
□□□ □□□□ □□□□□□□□□□ □□ □□□□□□	□□□□ □□□□□□□□□□ (□□□□ □□□□ □□□□ □□ □□□ □□ □□□□□□□□□□ □□□□ □□□□ □□ □□□□□ □□, □□□ □□ □□□ MTHFR □□ □□□□□□ □□ □□□□	□□□□□□□□ □□□□□□□□□□ □□□ (□□□□ 11)□ □□ MTHFR □□ □□□□□□ □□ □□□□□□□□ □□□□ □□□ □□□□□□□-□□□□□□ □□□□□ (Ulta Lab Tests,

	□□), □□□□ □□□□□□□□□□□□□ □□□□ (B12 □□ □□□□), RBC □□□□□□ (□□□□□□ □□ □□□□), □□□□ B12.	Request A Test) □□□□□ □□□□ □□□ □□ □□□□□□□□ □□□□□□ □□□□□ □□□□ □□□□ □□□□□ □□ □□□ □□□□ □□□□□□ □□□□□□□□□□ □□ □□□ □□□□□□□□□ □□□ □□□□□ □□□□□ □□□

1.2 — VCF □□□□: □□□□□□ □□□□ □□□□ □□□ □□ □□□□ □□□

□□□□ □□□□□ □□□□ □□□□ □□□□□ □□ □□□□□□□□□□ □□ □□□□□ □□□□□□ □□□□ □□, □□□ □□□□□□□ □□□ VCF □□□□ □□□□□□—□□□ □□□□□-□□□□□□ □□□□ □□ □□□□□□ □□□□□ □□□□ □□□ □□ □□ □□□□□□□ □□□□□□ □□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□ □□ "□□□□□□□□ DNA □□□□□□□□□" □□□ □□ □□□□□ □□□

- □□□□ VCF □□□□ □□□ □□□□□□□ □□□ □□□ □□□□□□□□ □□□□□ '□□ □□□□□ □□ □□□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□□ □□□ □□□□ □□□ □□□ □□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□□□□□□ □□□ □□□□ □□□
- VCF □□□□ □□□□□□ □□ □□□ □□□□□□□□□□ □□□□ □□□□□□ □□□□ □□ □□ □□□□□ □□□ □□ □□□□□□□ □□ □□□□ □□□□□□ □□□□ □□□ □□□ □□ □□□□ □□□□□ □□□
- □□□□□□ □□□□ □□□□ □□ (23andMe/Ancestry): □□□□ □□□□ □□□□ □□□□□□□□ □□□ □□□□ □□□ (raw) □□□□ □□□□□□□ □□□□ □□ □□□ □□□ .txt □□□□ □□□□ □□□ □□□□ □□□□□□□□□ □□ VCF □□□□□□ □□ □□□ □□□□□ □□ — □□□□ □□□□□□□ □□□ □□ □□□□□ □□□ □□□ WGS □□ □□□□ □□□□

[illegible] 2 — [illegible] — [illegible] 16 [illegible]

[illegible] — [illegible]

[illegible] biohacker_multi_domain_profiler.py [illegible]— [illegible] VCF [illegible] 16 [illegible], [illegible]

2.1 — [illegible]

[illegible]

```
python3 biohacker_multi_domain_profiler.py your_genome.vcf
```

[illegible] VCF [illegible] Recovery Kernel [illegible], [illegible] 16 [illegible] — [illegible] JSON [illegible]

2.2 — 16 [illegible]

[illegible]	[illegible]	[illegible]
NM	[illegible]	[illegible], [illegible] — [illegible], [illegible] [illegible]-[illegible], [illegible]
RC	[illegible]	[illegible], [illegible], [illegible] RC [illegible]-[illegible] ([illegible], [illegible]) [illegible] '[illegible] MTHFR [illegible] RC [illegible]
[illegible], [illegible]	[illegible]-[illegible]	[illegible], [illegible], [illegible] HM [illegible]-[illegible] ([illegible], [illegible]) [illegible] [illegible]-[illegible]

[illegible]		
SX	[illegible]	COMT [illegible] SX [illegible] ([illegible], PT-141, [illegible]) [illegible] ED [illegible] '[illegible]
[illegible], [illegible]	[illegible].	[illegible], BDNF [illegible], [illegible] CB [illegible]—[illegible] ([illegible], [illegible], [illegible]) [illegible]
MW	[illegible]-[illegible]	[illegible], [illegible], [illegible], [illegible] GLP-1 [illegible], [illegible], [illegible]
SL	[illegible]	[illegible], NAD+ [illegible], [illegible] SL [illegible]—[illegible] '[illegible] SL [illegible] = [illegible]
[illegible]	[illegible]-[illegible]	[illegible], [illegible], ACTN3 [illegible]
MX	[illegible]	[illegible] (SLC6A4), [illegible], [illegible] MX [illegible] = [illegible] = [illegible]
EM	[illegible]-[illegible]	NAD+ [illegible], [illegible], ATP [illegible] EM [illegible] = [illegible] - [illegible]
NP	[illegible]	APOE [illegible], [illegible], [illegible] APOE ε4 [illegible]—[illegible] ([illegible] APOE ε4 [illegible])[illegible]
[illegible]	[illegible]-[illegible]	[illegible]: [illegible]

		[illegible] CYP1A2, CYP2D6, CYP2B6, CYP3A4, CYP2C19 [illegible]-[illegible], [illegible] 5 ([illegible]) [illegible]
[illegible], [illegible]	[illegible]	HPA [illegible], [illegible], [illegible], [illegible], [illegible] HPA [illegible] (Sage COMT [illegible]) [illegible]-[illegible]
[illegible], [illegible]	[illegible]	MTHFR-[illegible]-[illegible], [illegible], [illegible] MTHFR [illegible], [illegible], [illegible] CV [illegible]
[illegible], [illegible]	[illegible]	[illegible], [illegible], [illegible] MTHFR [illegible] '[illegible] '[illegible] GH [illegible]-[illegible]
[illegible]	[illegible]	[illegible], [illegible]-[illegible] 15 [illegible] BP [illegible]: [illegible] = [illegible]-[illegible]; [illegible] = [illegible]

2.3 — [illegible]

[illegible] 16 [illegible], [illegible] biohacker_final_edition_with_json_import.html [illegible]:

1. [illegible] JSON [illegible], [illegible]
2. [illegible] HTML [illegible]
3. [illegible] JSON [illegible], '[illegible] JSON' [illegible] - [illegible] 16 [illegible]
4. [illegible]
5. '[illegible]alyse [illegible]' [illegible] '[illegible]—[illegible], [illegible]-[illegible]

6. [illegible]:

   * [illegible]
   * [illegible]
   * [illegible]
   * [illegible]
   * [illegible]

   [illegible]:

   * [illegible]
   * [illegible]
   * [illegible]
   * [illegible]
   * [illegible]

□□□□ 3 — MTHFR □□□□□□ □□□□□□ □□□□□ □□ — □□-□□□□□□□□□□□ □□□□ '□□ □□□□ □□□□

□□ □□□□□□□□□ — □□□□ **40%** □□□□□ □□ □□ □□ □□□ □□□ □□□□□□□□□□ □□□□ □□□

⚠ □□ □□□□□□ □□□□□□□□ □□□□ **MTHFR C677T** □□□□□□□□□ **(TT)** □□□ **A1298C** □□□□□□□□□, □□□ **C677T/A1298C** □□□□□□□ □□□□□□□□□□□ □□□□□□ □□□ □□**:** □□ □□□□□□ □□□□□ □□□ □□ □□□ □□□□□□ □□□□ □□□ □□□□ □□ □□□□□□□□□, □□□□□□ □□□ □□□□□□□□□ □□□□ □□□□□ □□□ □□□ □□□□□□□

□□ □□□□□□□ □□ □□□□□□□□□ 06 □□□□ MTHFR □□□ '□□□□ □□ □□□□' □□□□ □□□ □□ □□□ □□ □□□□ □□□ □□□□□ □□□ □□: MTHFR □□ □□□□□□□ □□□□ 40% □□□□□ □□□□ □□□□□ □□□ □□ □□□□□□□ □□ □□□□□□□□□□ □□□ 30-70% □□□ □□□ □□□□□ □□□ □□□□ □□□□□□ □□□□□□□ □□□□□ □□ □□□ □□□□ □□□□ □□□□□□ □□ - □□□□ □□□ □□□ □□□ □□□□ □□□□ □□□□□□

3.1 — MTHFR □□□ □□□□ □□ □□?

MTHFR (□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□) □□□ □□□□□□□ □□ □□ □□□□□ □□□□ □□□□□ □□□□□ □□□ 5-□□□□□□□□□□□□□□□□□□□□□□□□ (5-MTHF) □□□□ □□□□□ □□ — □□ □□□□□ □□ □□□□□ □□□ □□ □□□□□ □□□□□ □□□□□□□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□ □□□□□□□□□□ □□□ □□ □□□□□□□□□□ □□□□□□□□ □□□□ □□□ □□ □□□ □□□□□□ □□ □□□□ □□:

- □□□□□□□□□□□□□□□ □□□□□□□□ - □□□□□□□□, □□□□□□□□□, □□□ □□□□□□□□□□□□□□□, □□□□ □□□ □□□□□□□□□□ □□□□ □□ □□□□□□ □□ □□□ □□□□□ □□, □□ □□ □□-□□□□ □□□□□ □□□□□
- □□□□□ □□ □□□□□□ □□□ □□□□ - □□□□□ '□□ □□□□□□□□□□ □□□ □□□ □□□□□□□□□□ □□□ □□□□□□ □□□□ □□□
- □□□□□□□□□□□□□□□ - □□□□ 2 □□□□ □□□□□□ □□□□□□□□□□ '□□ □□□□□ □□□□ □□□
- □□□□□□□□□□ □□ □□□□□□□ — □□□□ □□□□ □□□□□□□□□□, □□□□ MTHFR □□ □□□□ □□□□□ □□, □□□ □□□□ □□□□ □□□□□□□□□□ □□□ □□□□□□ □□□-□□□□ □□□□ □□□□ □□, □□□ □□□□□ □□□□□□ (□□□ □□□□□□ '□□ NMDA □□□□□□□), □□□ □□□□□□ □□□□ □□□□□□□□□ □□□□ □□□□ □□□□□□□□□□ □□ □□□□□ □□□
- □□□□□□ □□□□□□□□□—□□□ □□□□□□□ □□ □□□□□□□□□ □□ □□□□□□□□□□-□□□□□□ □□□□□□□□□□□ □□ □□□ □□□□□ □□□

3.2 — ADHD □□ □□□ □□□□□ □□□ □□ □□□□□□ — □□ □□□ □□□□ ADHD □□□□ □□ □□□□□

□□ □□□□□□□□□ — □□ □□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□ □□□ □□□□ □□□ □□□□□, □□□ **5-MTHF** □□□□□ □□□ □□ □□□□ □□□

□□ □□□□□□□ □□ MTHFR □□□ □□□□ □□□ □□□□□□□□□ □□□□□□□ □□□□□□ □□□□ □□□ □□, □□□□□□ □□ □□□□ □□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□ □□: □□□□ □□□□ □□□□□ □□□ ADHD □□ □□□ □□□□□ □□— □□□ □□□□ □□ □□ □□□□□□ □□□ □□□□ □□□□ □□□□□,□□□ □□□□□□ □□□□

[illegible]— [illegible] MTHFR [illegible] [illegible], [illegible]

[illegible]:

7. MTHFR [illegible] BH4 ([illegible]) [illegible] — [illegible] ([illegible]) [illegible] ([illegible]) [illegible]
8. [illegible] BH4 → [illegible] → [illegible]
9. [illegible]: [illegible], [illegible], [illegible], [illegible] — [illegible] ADHD [illegible]
10. [illegible] ADHD [illegible] ([illegible], [illegible]) [illegible]-[illegible]—[illegible] ADHD [illegible]
11. [illegible], [illegible] -- [illegible] -- [illegible] MTHFR [illegible] 5-MTHF [illegible], MTHFR [illegible] (UMFA) [illegible]
12. 5-MTHF (L-[illegible]) — [illegible] MTHFR [illegible] — [illegible] '[illegible] BH4 [illegible] → [illegible] '[illegible] → [illegible] '[illegible] ADHD [illegible]

[illegible]:
The implication: before accepting an ADHD diagnosis and beginning stimulant medication, confirm your MTHFR status and trial 5-MTHF. For MTHFR variant carriers, the 'ADHD' may resolve substantially with adequate methylation support — leaving stimulant medications as unnecessary exposures to substances with significant dependency potential.

[illegible]:
[illegible]: ADHD [illegible], [illegible] MTHFR [illegible] 5-MTHF [illegible] MTHFR [illegible], [illegible] 'ADHD' [illegible]—[illegible], [illegible]

3.3 — [illegible] 5-MTHF [illegible]

⚠ [illegible] **MTHFR** [illegible] **,** [illegible]-[illegible] '[illegible]**—**[illegible]

□□□□□□ □□□□□ (MTHFR □□□□□□□□□□□□□ □□ □□ □□□□ □□□□□□□ □□□)।	L-□□□□□□□□□□□□ / 5-MTHF (□□□□□ □□□□□□ □□□)	□□ □□□□□□ □□ □□□ □□, □□ □□□□□ □□□
□□□□□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□: □□□□□□□□□ □□□□□□□□□□□□□□, □□-□□□□□□□□ □□□□□□□□, □□□□□□□□□□ □□□□□□□, □□□□□□□□□□ □□□□, □□□□□□□□□ □□□□□□□□, □□□□□□ □□□□□□□□□ □□ □□-□□□□□□□□ □□□□□□।	□□□□□□ □□ □□□□ □□□□□□ □□□□ □□ MTHFR □□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□ □□□□□□□: Deplin (□□□□□□□), Metafolin (Solgar), Quatrefolic (□□□□-□□□□)। □□□□ □□ □□□□□□□□□ □□□□ '□□ 'L-methylfolate' □□□□ '5-MTHF' □□□□□□ □□□□□, □□□□ □□ □□□□□□ □□□□ '(6S)-5-methyltetrahydrofolate' □□□□□ □□□□□□□□ □□□□।	□□□□□ □□□□□□□□□□ □□□□□□□ □□□□ □□□□□□□ □□□□□ □□ '□□ '□□□□□□ □□□□□' □□□□□□ □□□□□ □□, □□□□ □□ □□ □□□□ □□ □□ MTHFR □□□□□□□□ □□□□□ □□□□ □□□□□□□□□□□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□□ 5-MTHF □□ □□□□□□ □□□□□ □□□□□ □□ '□□ '□□□□□□' □□□□□□ □□□□□ □□, □□□□ □□□□□□ □□□□□ □□□□□ □□ □□□□ □□□□ □□□□□□।

3.4 — □□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□

□□ □□□□□ □□□□□ MTHFR □□□□□□□□ □□□□□□□□□ '□□ □□□□□ □□□□□□ □□, □□□□□□□ □□□□□□ □□□□ □□□□□□□□□ □□ □□□□□□ □□□□□ □□□□□□□ □□ □□□□□ □□ □□□□□ □□□□ □□□□□□□ □□ □□□□□□□□ □□□□□□ □□:

□□□□□□□□□□□	□□□□□	□□□□□□□	□□□□□?
5-MTHF (L-□□□□□□□□□□□□□) - □□ □□□□ □□□□□□□□ □□□□□ □□□□	400–1000 mcg □□□□□□□□□□	□□□□□□ □□□□□—□□□□□ □□ □□□□□ □□□□□□□ □□□□□□□□ □□□□ □□□□□□□, □□□□□ □□ □□□□□□□□□ (consistency) □□□□□□□□ □□□□□□□□□□□ □□□□	□□ □□□□□□ □□□□□□ □□□□ □□ □□□□□ □□□□ MTHFR □□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□ 400mcg □□□□ □□□□□□ □□□□ □□□□ 4 □□□□□□□□ □□□□□ □□□□□ □□ □□□□□□□□□ □□□□□ □□□□ MTHFR □□□□□□□□□□□□ □□□□□□□□□ □□, 1000mcg □□□□ □□□□□□□ □□□□□□ □□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□ '□□ □□□□□□□□□□□ □□□□ □□□□□ □□□□□□ □□□□□□ □□: □□□□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□□□—□□□□□ □□□□□□ □□ □□ □□□□□□□□□□□ □□□□□ □□□□□ □□ □□□□□ □□ □□□□ □□□□□□□ □□ □□□□□ □□□□
□□□□□□□□□□□□□□□□□□ (□□□□□□ □□12)	1000–2000 mcg □□□□□□□□□□□	□□□□□□	□□ □□□□□□□□□□□□ □□□□□ □□□□□ 5-MTHF □□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□ (□□□□□□□□□□□□□□□ □□□□□, □□□□□□□□□□□□□□□□□ □□ □□□□□, □□□□□ □□□□□ □□) □□ □□□□□□ B12 □□□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□ □□□□: 5-MTHF + □□□□□□□□□□□□□□□□□ □□□□□□ □□ □□□□□□□ □□□□□ □□ □□ □□ □□□□ □□□□□□□ 5-MTHF □□□□ □□ □□ □□□□□□□ □□□□□□□□□□□□□□□□ □□ □□□□□ □□□□
P5P (□□□□□□□□□□□-5-□□□□□□□ — □□□□□□	25–50mg	□□□□□□	□□□□□□ B6 □□□□□□□□□ □□□□□□□□□□□□□□□□□ □□□□□ □□ - □□

□□6)			□□□□□□□□□□ □□□□ □□ □□□ □□□□□ □□□□□ □□ □□ □□□□□□□□□□ □□□ □□□□□□ □□□ □□□ □□□□□□□□□ □□□□ □□□□□ □□□ □□□□ P5P □□ □□□ □□, □□□ □□□□□□□□□□ □□□ □□□□□□□ □□□ □□□□ □□□□ □□□□ □□ □□□□, □□□□□ 5-MTHF □□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□ '□□ □□□□ □□□□ P5P □□□□ □□ □□□□□ □□□ - □□□□□□□□□□□ □□□□.
□□□□□□□□□□ □□□□□□□□□□	400-600 □□□□□□□□□□ □□□□□□□□□□	□□□□ □□□ □□□□□	□□ □□ □□□□□□□□□□ □□□□ □□□□□□□□□ □□ □□□ □□□□□□□ □□□ □□□□□□□□□□ □□ □□□ □□□□□□□□□□ □□□□ □□ □□□□□□□ □□□ □□□□□□□□ □□ □□□□ □□, □□□□□ □□□ □□□□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□ □□□□□□□□ □□□ □□□□ □□□□ □□□ GABA □□□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□□□□□□□□ □□□ □□□□□□ □□□□ □□□
□□□□□□□□□□□□ (B2)	25–100mg	□□□□□ □□□□□	MTHFR □□□□□□□ □□□ □□□□□□□□□ (B2) □□□ □□□□□□□□□ □□□□ □□□ □□□□□ □□ - □□ □□□ FAD-□□□□□□ □□□□□□□ □□□ C677T □□□□□□□□□□ □□□□□□□□□ □□□□, □□□□□□□ □□□□□□□□□□ □□□□ □□□□□□ □□□ □□ □□ □□□□□□□□□ □□ □□□□□□ □□□ □□□□□□□□□□ □□□ □□□□ □□ □□□□ □□ □□□ MTHFR □□□□□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□, □□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□ □□ C677T □□□□ □□□□□□ □□ □□□ □□□□□□□ □□□ □□□
□□□□□ / □□□□□□ (□□□□□□□□□□□□□□□□□□□□) □	500–1000mg	□□□□□	BHMT □□□□□□□ □□□□□ □□□□□□ □□□□ □□□ □□□□ □□□□□□□ □□□□□ □□□□ — □□ □□□ □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□□□□□ □□□□ □□ □□ MTHFR □□□□□□□ □□□ □□□□□□ □□□ □□□ □□□ '□□ MTHFR □□□□□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□□□, □□□□□□ □□ □□□ □□□□ □□□□□□□□□□□□ □□ □□□□ □□□ □□ □□□□ □□ □□□□□□□□□□ □□ □□□ □□□ □□ □□□□□□□ □□□

□ □□□□□□□□ — □□□□□□□□□□ □□ □□□□□□□: **MTHFR □□□□ □□□□□ □□□□ □□□□ 3 □□□□□□□ □□□□ □□□□ □□□□□□□□□□ □□ □□□□ □□□□ □□□□: 8 µmol/L □□□ □□□□ □□□□□□□: 6–7 µmol/L.** □□ □□□□□□ □□□□□□□□□□ □□□□□□□ □□ □□□ □□ □□□ '□□ □□□□□ □□□□□□□ □□□□□□ □□ □□ □□□□□□ □□□□ □□□ □□ □□□□ □□ □□□ □□□□□

3.5 - MTHFR [illegible]

⚠ **MTHFR** [illegible] **→ MTHFR [illegible] +2מ'**

[illegible] B12 [illegible] MTHFR [illegible], [illegible] (methylation) [illegible] "[illegible] MTHFR [illegible] -

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible]

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

MTHFR [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] COMT [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible] [illegible] [illegible], [illegible] [illegible]	[illegible] ([illegible]) [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]
[illegible] [illegible]	[illegible] [illegible], HIIT ([illegible]-[illegible] [illegible] [illegible]), [illegible], [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible], [illegible], [illegible], [illegible] [illegible] ([illegible]-[illegible]), [illegible], [illegible]. [illegible] [illegible] [illegible]
[illegible]	[illegible] moderate [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] COMT [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] CYP1A2-[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] "[illegible]" [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

4.2 — [illegible] [illegible] [illegible]: DRD2 A1 [illegible]

[illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

COMT [illegible] [illegible] [illegible] [illegible] DRD2 A1 [illegible] [illegible] [illegible] [illegible]: 'RDS [illegible] DRD2 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

4.3 — [illegible]

[illegible]	[illegible]	[illegible]
MTHFR C677T [illegible]	[illegible], [illegible]	MTHFR [illegible] ([illegible] 3)[illegible]
COMT Val/Val ([illegible])[illegible]	[illegible], [illegible], [illegible] '[illegible]	[illegible]-[illegible], [illegible] (stimulants) [illegible], [illegible], [illegible], [illegible]
COMT Met/Met ([illegible])[illegible]	[illegible], [illegible], GHB, [illegible] '[illegible]	[illegible]
DRD2 A1 [illegible] (RDS)	[illegible]—[illegible], [illegible]	[illegible]-[illegible]
SLC6A4 [illegible]/[illegible] (5-HTTLPR)	[illegible] — [illegible], [illegible] MDMA, [illegible] ([illegible]), [illegible]-[illegible]	5-MTHF [illegible] 5-HTP, [illegible] (social anxiety) [illegible] MDMA [illegible] '[illegible], [illegible]
GABRA2 [illegible]	[illegible] GABA-A [illegible] "[illegible]" [illegible], [illegible] GABA [illegible]	[illegible] GABRA2 [illegible]—[illegible], [illegible] GABA-[illegible], [illegible] GABA [illegible]

OPRM1 [illegible] ([illegible] MOR [illegible])[illegible]	[illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible]

□□□□ 5 — □□□□□□ □□ □□□□□ □□□□ — □□ □□□□□□ □□ □□□□□□□ □□□ □□□□ □□□□ □□□□□□□

□□ □□□□□□□□□ — □□□□□□ **CYP450** □□□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□ □□□

□□□□□□□□ □□□□□□ □□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□□ □□□ CYP450 □□□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□ □□ □□□□ □□ □□□□ □□□ □□□□□□□ □□□□□□□ □□□ □□□□□□ □□□□□ □□□□□□□□□ □□□□ □□□ □□□□ □□ □□□□ □□□ □□ □□□ □□□□□ □□□□ □□□□ □□□ □□ □□□ □□□□□□□□□□□□□□□□ □□□□□□□ □□□□□□□ □□□

□□□□□□ □□ □□: □□□□□□ □□□□ □□□□□ □□□□□□□ □□□□□□ □□□ □□□□□□□ □□□ □□□□□ □□□□ □□ □□□□, □□□□□□ □□□□□□□□ □□□□□□□ □□□□□□□ □□□□ □□□ □□□□□□ □□□□ □□□ □□□□□□□□□ □□□ □□□□□□ □□, □□□ □□□□□ □□□□□ □□□ □□□□ □□□□ □□□□ □□, □□ □□□□□ □□□□ □□□ □□□□ □□ □□ □□□ □□□□□ □□□□□ □□□ □□□□ □□□□□ □□□□ □□□□ □□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□ □□□□□□□ □□□ □□ □□□□□□ □□ □□□ □□□ □□□□□ □□, □□□ □□□□□ □□ □□□ □□□□ □□□□□ □□ □□□□□

5.1 — CYP450-□□□□□□ □□□□□□□ □□□ □□□□□□□

□□□□□□ □□□□□□□□□	□□□ □□□□ □□□ □□□ □□ □□ □□□ □□□□□ □□□□□ □□□□ □□□□□□□ □□□ □□□: * □□□□□□□□ **(Naloxone)** * **COMT** * **DRD2** * **MTHFR** * □□□□□□ □□□□ **(Recovery Kernel)**	□□□□?
CYP2D6 *4/*4: □□□□ □□□□□□□□□□□□□□	□□□□□—□□□ □□□□□ □□□□□□□□□□—□□□ □□□□□ □□□□□□□□ (□□□□□□□□□□□□□□□□□, □□□ □□ □□□□□)—□□□□ □□□□□□□/□□ □□□ □□□□□□ □□□□ □□□□□□□—□□□□ □□□□□ □□ □□□□□□□ □□□ □□□□□□□□ □□□□□ □□□ □□□□□□□□□□□□□□ (□□□□□□□□□□, □□□□□□□□□□)—□□ CYP2D6 □□□□□□ □□□□ □□□ □□□□□ □□□□□□ □□ □□□□ □□□	CYP2D6 □□□ □□□□ □□□□ □□□ □□□□□□ □□□□ □□□□□ □□□ □□□□□ □□□ □□ □□□ □□□ □□□□ □□ □□□□, □□□□□ □□ □□□□ □□□ □□□□ □□ □□□□ □□□ □□□□□□□□ □□□□ □□□ □□ □□□□ □□□ □□□□□□□□ □□ □□□ □□ □□□□□ □□□□□ □□□ DXM □□□ □□□□□ □□□□□□□□□□ □□□□ □□□□ □□ □□□□□, □□ □□□□□□□□□□□□ □□□□□ □□ □□□□ □□ □□□□ □□□ □□□□□□□: "□□ □□□□□ □□□□ □□□□ □□□□ □□ □□□□□□ □□□ □□□ □□□□ □□□ □□□ □□□ □□□□ □□□"
CYP2D6 □□□-□□□□ □□□□□□□□□□□□□□□	□□□□□ - □□□ □□□□ (□□□ □□□□□ □□□□)□ □□□□□□□□□□ - □□□□ □□□□□□□□ □□□□ □□ □□□□□ - □□□ □□□□ □□□ □□□□□□□ □□□□	□□□-□□□□ CYP2D6 □□□□□ □□□ □□□□ □□□□□ □□□ □□□□□□ □□□□ □□□□□ □□—□□□□□□ □□□□ □□□□□ □□□ □□□ □□□□□ □□□□□□ □□ □□□□

		[illegible]-[illegible] [illegible], [illegible]
CYP2B6 *6/*6: [illegible]	PCP/[illegible]/[illegible]—[illegible] ([illegible].[illegible].[illegible] [illegible])—[illegible]—[illegible] '[illegible]' [illegible]	CYP2B6 [illegible] PCP [illegible] '[illegible] — [illegible] ([illegible]) [illegible] CYP2B6 *6/*6 [illegible]: [illegible]
CYP3A4 [illegible] ([illegible])[illegible]	[illegible] CYP3A4 [illegible] ([illegible], [illegible], [illegible] HIV ARTs) [illegible]: [illegible], [illegible] (7-OH-MG), [illegible], [illegible], [illegible] CYP3A4 [illegible]	CYP3A4 [illegible], [illegible] '[illegible]' [illegible]-[illegible] [illegible], [illegible]
CYP1A2 CC [illegible] ([illegible])[illegible]	[illegible] ([illegible] 300mg, [illegible]): [illegible] '[illegible] 12 [illegible] 100-150mg[illegible] [illegible] CYP1A2 [illegible]	CYP1A2 [illegible]-[illegible] (half-life) 7–9 [illegible] 3 [illegible] 12 [illegible] CC [illegible], [illegible]
ALDH2 *2/*2 [illegible]	[illegible] - [illegible], [illegible] '[illegible]	ALDH2 *2/*2 [illegible] ([illegible]) [illegible]—[illegible], [illegible]

		'□□ □□□□□□□□□□ □□□□□□□□ □□ □□□□□□ □□ □□□□□ □□ □□ □□□□□□ □□□□
MTHFR C677T □□□□□□□□□□□□□	□□□□□□□ □□□□□□□— □□□□□ □□□□□□ □□□□□□□□ □□ □□□□□□□ □□ □□□□□ □□□□□ □□ □□□□□□ □□ □□□□□ □□□□ □□□□□□□ □□ □□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□□ □□□□□ □□□□□□□— □□□□ □□ □□□□□, □□□□□ □□□□ 5-MTHF □□ □□□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□— □□ □□□□□□□□□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□□ □□□□	MTHFR □□□□□□□□□□□□ □□□□ □□□□□□□ □□ □□□□□□□ □□□□□ □□□□□□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□□ □□□□□□ □□ (MTHFR □□□□□□□ □□ □□□□□ □□□□□□ □□ + □□□□□□□ B12 □□□□ □□□□□ □□□□□ □□ → □□□□□□□□□ □□□□□□□□ □□□□□□ □□□□□□ □□)□ □□ □□□□ □□ □□□□□□ □□□□□□ □□□□□□□□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□□, □□□□□ □□□□ □□□□□□ □□ □□□□□□ □□, □□ □□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□ □□□□□; □□ □□ □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□

5.2 — □□□□□□□□ □□□□□□□□□ □□□□□□□□□□ '□□ □□□□□□ □□□□□ □□□□□ □□□□ □□ □□□□□□□

□□□□□□□ □□□□□□□□□	□□□□□ □□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□:	□□□□□□□□□□□□□□□ □□□□□□
	* □□□□□□ (□□□□□□□□□) * □□□□□□□□□ * □□□□□□□□ * □□□□□□ * □□□□□□□□□□□□□□□ * □□□□.□□□□.□□. * □□.□□.□□□□.□. * □□□□ * □□□□□□□□ * □□□□□□□□ * □□.□□.□□□□.□□. * □□□□□□□□ * □□□□□□□□□□ * □□□□□□□□□□□□□ * □□□□□□□□□□□□□□□□□□□ * □□□□□□□□ * □□□□□□□□□ * □□□□□□□□□ * □□□□□□□□□ * □□□□□□□□□ □-□□□□□□ * □□□□ * □□□□□□□□ * □□□□□□□□□□ * □□□□□□□□□□□□□ * □□□□□□□□□□□□□□□□□□□ * □□□□□□□□ * □□□□□□□□□ * □□□□□□□□□	

	* □□□□□□□□□ * □□□□□□□□ □-□□□□□□ * □□□ * **Recovery Kernel** * **Naloxone** * **COMT** * **DRD2** * **MTHFR** * **Blueprint** * **findahelpline.com**	
GABRA2 □□□ □□□□□ □□□□□ □□□□□□□□□□□□	□□□□□□□□ (□□ □□□□□ □□□□□ □□), □□□□□□□□□□□□□□□□□□, GHB, □□□□□□□□□□□□□□□□	'□□□□□ □□□□ □□□□□□□□□□□' (□□□□□□□□□□). GABRA2 □□□□□□□□ GABA-A □□□□ □□□□ □□□□□□□□□ □□□□□ □□□□ □□□□ □□□□□□□□□ + □□□□□□ GABA □□□□□□□□□ = □□ □□□□□□□ □□□□ □□□□□□□ □□□□ □□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□□ □□□□□ □□ □□□□ □□ □□□□□□□□□ □□ □□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□ □□□□
AKT1 T/T	□□□□ (□□□□□□□□□□□□□ □□□□□□□□□□□□ □□ □□□□□□□ □□□□□), □□□□□□□□□□□ □□□□□□□□□□□□□□ (□□□□□ □□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□□)□	AKT1 T/T □□□□ □□□□□ □□□□□□□□ □□ □□□□□ CB1 □□□□□□□□□ □□ □□□□□□□□ □□□□ □□□□□□□□□□ □□□□□□ □□□□□□□ □□ □□□□□ □□□□ □□ □□□□□□□□□ □□ □□□□□□□ □□ AKT1 C/C □□□□□ □□□□□□□ □□ □□□□□□□□□□ □□ □□□□□ □□, T/T □□□□□ □□□□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□ □□ □□□□□ □□, □□□□ □□□□□ □□□□ THC □□□□□ □□□□□□□□□ □□□□□□
SLC6A4 □□□□□□/□□□□□□□□	□□□□□□□□□ (MDMA) □□□□ □□□□□ (□□ □□□□□ □□□□□ □□□□□□ □□□□□ '□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□□□□□ □□ □□□□□□□□□□□ □□ □□□□□ □□), □□□□□ □□ □□□□□-□□□□□□□□□□□□ □□□□□□□□□□□ (serotonin-releasing) □□□□□ □□□□□□□□	□□□□□□□/□□□□□□ SLC6A4 □□□□□ □□□□□□□□ □□ □□□□□ □□□□ SERT □□□□□□□□□□□□ □□□□□□ □□□□ MDMA □□□□□ □□□□-□□□□□ □□□□□ □□□□□□□□□□□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□□□□ □□□□□□□□□□□ □□□□□□□□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□ '□□ □□□□□□ □□□□□□□ □□□□□□ □□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□□□□ □□□□
OPRM1 □□ □□□□□□□	□□□□□□□□□□□ (□□□□□□ □□□□□□□□ □□ □□□□ □□□□□ □□ □□□□ □□□□□□ □□—□□ □□□□ □□□□□□□□□□□□ □□□□□ □□□□□ □□ □□□□□ □□), □□□□□□□□□□ □□□□□□□□□□□ (□□□□ □□□□□ □□□□□□□□□□—□□ □□□□ □□□□□ □□□□□□□□ □□)□	□□□□ □□□□□ '□□' □□□□□ MOR □□□□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□ □□□□ □□□□□□□□□ □□□□□ '□□ □□□□□□□□□□ □□□□ □□□□□□□□□□□□□□ □□□□ □□□□□ □□, □□□□ □□□□ □□□□□ □□□□□□□ □□ □□□□□□□□□ □□ □□□□□ □□—□□ □□□□□ □□□□□ □□□□□□□ □□ □□□□ □□□□□□□□ □□□□□□ □□□□ □□ □□□□□□□□ □□□□ □□ □□□□□□□□□ □□ □□□□ □□ □□□□ □□□□□□□□□ □□□□□ OPRM1 □□□□ □□□□□ '□□/□□' □□□□□□□ □□, □□□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□ □□□□ □□□□□□□□ □□□□ '□□ □□□□□□□ □□□□□□□□ □□, □□□□□□□□ □□□□ □□□□ □□□□

		[illegible] [illegible] [illegible]

[illegible] 6 — [illegible] — [illegible]

[illegible] — [illegible]-[illegible]: [illegible], [illegible]

⚠ [illegible] '[illegible], [illegible] **16** [illegible], [illegible]

[illegible], [illegible], [illegible] (genetic profile) [illegible] (supplements) [illegible] (peptides) [illegible]-[illegible] (prevention stack) [illegible] - [illegible]

6.1 — [illegible]

[illegible], [illegible] MTHFR [illegible], [illegible], [illegible]:

[illegible]	[illegible]	[illegible]	[illegible]
5-MTHF ([illegible] MTHFR [illegible])	400mcg (MTHFR [illegible]) [illegible] 400–1000mcg (MTHFR [illegible])	[illegible]	[illegible], [illegible]
[illegible] (B12)	1000 mcg [illegible]	[illegible]	5-MTHF [illegible]—[illegible], [illegible]
[illegible]	400 [illegible]	[illegible]	[illegible] GABA-A [illegible] NMDA [illegible]

			[illegible] 300 [illegible], [illegible]
[illegible]-3 [illegible] + [illegible] ([illegible]- [illegible])।	1-2 [illegible] DHA + 1 [illegible] EPA [illegible]	[illegible], [illegible]	[illegible]-[illegible] 60% [illegible]—[illegible].[illegible].। [illegible]

6.2 — [illegible]-[illegible]

[illegible]-[illegible], [illegible]-[illegible]।

- [illegible] ([illegible]) [illegible]: 5-[illegible] ([illegible]), [illegible]-[illegible] ([illegible]) - [illegible] '[illegible]
- [illegible] MX ([illegible]-[illegible]) [illegible]: [illegible], [illegible], [illegible] — [illegible]
- [illegible] ([illegible]-[illegible]) [illegible]: [illegible]/[illegible]+ [illegible], [illegible] 10 — [illegible]
- [illegible] ([illegible]) [illegible]: [illegible].[illegible].[illegible]./[illegible], [illegible]-[illegible] - [illegible].[illegible].[illegible].[illegible].[illegible]. [illegible]
- [illegible] ([illegible]) [illegible]: [illegible], [illegible]-[illegible], [illegible] — [illegible] APOE [illegible]
- [illegible] SL ([illegible]-[illegible]) [illegible]: [illegible] (0.5mg), [illegible] — [illegible]
- [illegible] ([illegible]-[illegible]) [illegible]: [illegible]-[illegible], [illegible], [illegible] — [illegible] MTHFR [illegible]-[illegible]

[illegible], [illegible], [illegible]
[illegible], [illegible], [illegible]
[illegible] — [illegible], [illegible]: Recovery Kernel, Naloxone, COMT, DRD2, MTHFR, Blueprint, findahelpline.com
[illegible]: [illegible], [illegible], [illegible], [illegible], [[illegible]]।
[illegible] — [illegible]: not optional / mandatory / do not run this module / medical help is not failure.

6.3 — [illegible]:

[illegible] — [illegible] '[illegible]

[illegible] - [illegible], [illegible], [illegible], [illegible], [illegible] Val/Val [illegible], [illegible] RDS [illegible], [illegible] Met/Met [illegible] MTHFR [illegible]

- [illegible] '[illegible]:

  * [illegible]
  * [illegible], [illegible]
  * [illegible]
  * [illegible]
  * [illegible], [illegible] '[illegible]
  * [illegible]
  * Recovery Kernel, Naloxone, COMT, DRD2, MTHFR, Blueprint, findahelpline.com

- [illegible] — [illegible] "[illegible]" [illegible]; K2 [illegible] D [illegible]; [illegible]
- [illegible] ([illegible], [illegible], [illegible], [illegible]) [illegible] CYP1A2 [illegible] COMT [illegible]
- [illegible], [illegible] 5-HTP [illegible]
- [illegible]-[illegible] — [illegible]-[illegible]

□□□□ 7 — □□□□□□ □□□□□□□□□□ — □□□□ □□ □□□ □□ □□□□□□□□.

□□ □□□□□□□□□□ — □□□□□□ '□□ □□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□ □□ □□□□□□ □□□□

□□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□□ □□□□□□ □□□□□□□□ □□□ □□□□□□ □□□□□□ □□□□ □□□ □□ □□□□ □□ □□□□□□□ □□□□□□□□□□□□ □□ □□□□□□□ □□□□ □□□ □□□□□□□ □□□□□□□□□□ □□□□ □□—□□ □□□□□□□□□□ □□□□□□□□ □□□□□□□ □□ □□ □□□ □□□□□□□ □□□□□□ '□□ □□□ □□□□ □□□ □□□□-□□□ □□□□□□□□□□□□ □□□□ □□ □□□□□□ □□ □□□ □□□ '□□ □□□□ □□□□□ □□□□□□ □□: □□□□□□ □□□□□ □□□□, □□□ □□ □□□□□□□ □□□□□ "□□□□□□□□□" □□□ □□□□ □□□□□ □□ □□□□□□□□ □□□□ □□□□ □□□□□□

7.1 — □□□□ □□□□ □□□□□□□□

□□□□ □□ □□□□□	□□□□ □□□□□□ □□□□□□	□□□□□□ □□□□□□□□□□□ □□ □□□□ □□□□ □□□
□□□□□□□ □□□-□□□□ (□□□ □□□□□ □□□□ □□□□)□	BPC-157 (□□□□ □□□□□, □□□ □□□□□, □□□□□□□) □□□-□□□□□ □□□□□ □□ □□□□ □□ □□□ □□□□□ □□ □□□□□□□ □□□-□□□□ □□□ □□ MX □□□□□ □□□□ □□□□ □□ □□□ Selank (□□□□□ □□□ □□□□)□ □□ CB □□□□□ □□□□ □□□□□□ □□□□□□□ □□□□□ □□□□□ □□ □□□ Semax.	□□□□□□ □□□□□ □□□ □□□□□ □□□□ □□ □□□□□ □□ □□□□ □□ □□□□ □□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□□□ □□□ □□□□□□□□ □□ □□□□ □□□ □□□□ □□□□□□□ □□: "□□□□□□□□ □□□□", "□□□□□□□ □□□□□ □□□□□□", □□□ "□□□" □□ □□□□□□□□
□□□ □□□□□□□□ □□ □□□ (□□□□ □□ □□□, □□□□□□□□, □□□ □□□□□)□	BPC-157: □□□-□□□□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□□□ □□□ Semax: □□□□□ □□□□□ □□ □□□□□□ □□□□ '□□ □□□ □□□□□ Ipamorelin: □□□□ MP □□□□□ □□□□ □□□□□ □□□□□ □□ □□□ □□□-□□□□□□□□ □□□□□ □□□□□ □□□□□□ □□□ □□□ □□□ □□□	□□□□□□□□ □□□□ □□ □□□□□ □□□□ □□□□□□ □□ □□□ □□□□□□ □□□□ □□□□ □□□ □□ □□□□ □□□ □□□□□ □□□□□□□□ □□□ □□□□□ □□ □□ □□□□□□□ □□□□ □□□□ □□□□.
□□□□□ □□□□ □□□ □□□□□□ □□ □□□□□	□□□□□□ □□□ □□□ '□□ □□□ □□□□□□□□ □□□□□□□ □□□□□□□ □□ □□□ □□□□ □□□ □□□□ □□□ □□□□ □□□□ □□□□ □□□ □□□□□□□□□ (□□□□□□□□ □□□□ □□□) □□□□ □□□□□□□□ □□□ □□□□□□□ □□□ BPC-157 □□□□ □□ □□□□ '□□ □□□ □□□□ □□□	□□□□ □□ □□□□ (□□□□□□, □□□□□□, □□□□□□, □□□□□□□□□□□□)□ □□□□□□□ □□□□□□ COMT □□□□□□□□□□ □□□ □□□□□□□□: □□□□ □□ □□□□ □□□ □□□□□ □□□□□□□ □□ □□□ □□□□□ □□ □□□ □□ □□□□□□□□□ □□□□□□ □□□ □□□ □□□□ □□ □□□□
□□□□□□ □□□ □□□ □□□ □□□□□□□	BPC-157: □□ □□□ □□□□□□□ □□□□□□ □□ □□□□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□ □□□□ □□ □□ □□□ □□ □□ □□□□□□□ □□□□ □□□□□ □□□□□□ □□ □□□□ □□□□□ □□□	□□□ □□ □□□□□ □□□□□□□□ □□□□□□ □□□□□□ (□□□□□□□□ □□□□□□□□□ □□□□ □□□ □□□□□□ □□□ □□□□□ □□□□□□ □□□□□ □□ □□ □□□□□□□ □□□)□ □□□□□□□ □□□ □□□□ □□□□□□ □□□-□□□□□□□ □□□□□□□□□ □□□□□□

	TB-500: □□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□□□□□ □□ □□□□□□ □□□□□□ □□□□ □□□□□□□□□ □□□□□□-1: □□□□□ □□□□□□ □□□□□□□ □□ □□□□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□	□□□□□ □□□□
□□□□ □□ □□□□ □□□□ □□□□□□□□□ □□□□□□ (□□□□□□□□, □□□□□□ □□□□)□	□□□□□□□□□, □□□□□□□□ □□□□ □□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□ □□□□□□□□□□□ □□□□□ □□□□ □□□□-□□□□□□ □□□□□ □□□□□□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□□□ SL □□□□□□ □□□□ □□□□ □□□□□ □□□□□□.	□□□□□□□□□ □□□□□□ □□ □□□□□□ (□□□□□□□□ □□ □□□□□□, □□□□□□ □□□□□)□ □□□□□□ □□□□□□□ SL □□□□□□ □□□□□□ □□□□□□□ □□ □□□□□□ □□□□□□□□□ □□□□□ □□, □□□□□□□□ □□□□□ — □□□□□□□□ □□□□ □□□□□ □□□□□ □□ □□□□□ '□□ □□□□□ □□□□□□ □□□□
□□□□□ □□□□ □□□□□□□□ □□□□ □□□□□□ □□ □□□□□□ (30+)□	□□□□□□□□□ (□□□□□□□□□ □□□□ □□□□□□□□ □□□□□)□ EM □□□□□□ □□□□ □□□□ NAD+ □□ □□□□ □□□□□ □□□□□ □□□□□□ □□□□□□ □□ □□□□□□□□ NP □□□□□□ □□□□ □□ □□□□□□-□□□□□□□□□□□□ □□□□□□	□□□□□ APOE □□□□□□ (ε4 □□□□□ □□□□□□ □□ □□ □□□□ □□□□ □□□□□□□)□ NP □□□□□□ □□□□□□ EM □□□□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□□□□ □□ □□□□□□□□□□□ □□□□ □□□□□□□□ □□ □□□□□□□ □□ □□□□□□ □□□□□ □□□□

7.2 — □□□□□□□ □□□□□□□□□ □□ □□□□□□ □□□□□□

13. □□□□□□ □□□□ □□□□□, □□ □□□□ □□ □□□□ □□□□ □□□□ □□ □□□□ □□□□□ □□□□□
14. □□□□□ □□□□□□□□ □□□□□□□□□ □□□□ □□□□ (□□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□)□
15. □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□□□□ □□□□ □□□□□□
16. □□□□□ □□□□ □□□□□ — □□□□□ □□□□□ □□□□□ '□□ □□□□□□□ □□□□□□ □□□□
17. □□□□□□□□□□□ □□□□□□□□□□ □□□□ □□ □□□□□□□ □□□□□□□□□□□ □□□□□ □□: □□□□□□□□ □□□□□□□ (□□□□□□□ □□□□□□□□□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□□□), □□□□□□□ □□□□□ □□□□□□□ (□□□□□□□□□ □□□□ □□□□□□□ □□□□ □□□□□□□), □□□□ □□□□ (□□□□□□□ □□□□□□□□□ □□ □□□□□□□)□
18. □□□□□□ □□□□□□□□ □□□□□ □□□□□□□□□□ □□ □□□□□, □□□□ □□ □□ □□□□□□□□ □□□□ □□□□□ □□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□
19. □□□□□□ □□□□□□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□□□ □□□□□, □□□□□□□ □□□□□□□□□ □□□□□□□□□□ □□□□ □□□□□□□, □□□□□□□□ □□□□ □□□□□□□□ □□□□□ □□ □□□□□ □□□□□□ □□□□□□□□

□□□□ 8 — □□□□□ □□□ □□□□□ □□□□□□□□□ — □□□□□□ □□□□□□□ □□□ □□□□□ □□□□□

□□ □□□□□□□□□ — □□□□□□□□□ **03** □□□□ □□□□, □□□□ □□□ □□□□□ □□□□ — □□□□ □□□ □□□□ □□ □□□ □□□□□□ □□ □□□□□ □□□□□□ □□ □□□□□□□ □□□□□□□

□□ □□□□□□□ □□ □□□□□□□□□ 03 (□□□□□ □□□□□□□) □□□□ □□□□- □□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□ □□□□□□ □□□ □□□ □□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□ □□: □□□ □□□□□ □□□□□ □□□□□□ □□□□ □□□□ □□ □□□□□□□□/□□□□□□□□/□□□□□□□□□□ □□ □□□ □□□ □□□ □□□□ □□, □□ □□□ □□□□□□ □□ □□□ □□□□ □□ □□□□ □□□ □□□ □□□□

□□□□□ □□□□□□□ □□ □□□□□□□ □□□□ □□□□□□ □□□ □□ □□□ □□□□ □□ □□ BDNF (□□□□□ □□□□□□ □□□ □□□□□□□□□□□□□□), □□□□□□□□ (□□□□□ □□□□□ □□□□ □□□□), □□□□□□□□□ (□□□ □□□ □□□□ □□□ □□□□), □□□□□□□□ (□□□ □□□ □□□□□□ □□□□ □□□□□□□), □□□ □□□□□□□□□□ (□□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□) □□□□ □□□□ □□□ □□□ □□ □□□□□□□□ □□ □□□ □□□ □□□□□□ □□□□ □□□ □□□□□ □□□□□ □□□□□ □□ □□□□□□ □□□ □□□-□□□□ □□□ □□□□□□□ □□□ □□□

8.1 — COMT-□□□□□□ □□□□□ □□□□□□□□□□

□□□□□□□	□□□□ □□□□□ □□□□□□□□□	□□ □□□□ □□
□□□□□□ — □□□/□□□ COMT	□□□-□□□□□□ □□□□ □□□□□ □□□□□□ (HIIT): □□□□□ □□□□ □□□□-□□□ 3-4 □□□□ □□□□□□□ □□□□□ (□□□□□□□, □□□□□□, MMA, □□□□): □□□□□□□ □□ □□□ □□□□□□ □□□ □□□□□□□□□ □□□ □□□□□: □□□□□□ □□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□ □□□ □□ □□□□□ □□□□□ □□ □□ □□□□ □□ □□□□□□□□□ □□□ □□□□□□□□□□ □□□ □□□□□□□: □□□□□□ □□ □□□ □□□□ □□□□□□ □□□□ □□□□□□ □□□ □□□□□□□□□ □□□□□ (5K, 10K, □□□□□□ □□□□□□)□	□□□□□ □□□ □□□□□□□□□ □□□□□□ □□ □□□□□ □□□ '□□ □□□□ □□□□ □□□□□□□ (□□□□□ □□ □□□□, □□□□ □□□□□)□ □□□□□ □□□ □□□□ □□□□ □□□□□ □□ □□□□ □□ □□ □□ "□□□□□□□" □□ □□□□ □□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□□□ □□□-□□□□□□ □□□□ □□□ □□□□□□□□ □□ □□□ □□□ □□□□ □□□□ □□ □□□□□
Sage — Met/Met COMT	□□□□ (□□□ □□□□ □□□□□□□□ □□□ □□□□□□, □□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□): □□ □□□□□ □□□ '□□ □□□ □□□ □□□□ □□ □□ □□ □□□□ □□□□□□ □□□□□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□: □□ □□□ □□□□□ □□□□□□ □□□ □□□ □□□ '□□ □□□□ □□□□□□□ □□□□ □□, □□ □□□□□□ □□□□ □□□□□□□ □□□□ '□□ □□□□ □□□□□ □□□□□□ □□□□□□□□□□: □□ □□□ □□□□□□ □□□ □□□□ □□□□□ □□□□□ □□□□□□□□□□ □□, □□ □□□□□ □□□ '□□ □□□ □□□ □□□□	□□□-□□□□□, □□□□□□□□□□, □□□-□□□□□□□□ □□□□ □□□□□ □□□ □□□□ □□□ '□□ □□□□□: □□ □□□ (Sage) □□□□ □□□□ □□□□□□ □□□ □□ □□□□□ □□□□□□□□□□□ □□ □□□ □□□ □□□ □□□ □□□□ □□□ □□□ □□ □□□□ □□□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□□ □□ □□□ □□□□□ □□—□□□□□□ □□□□□ (adrenal surge) □□□□□□ □□□ □□ □□□□ □□□□□□ □□□□□□□□□□□ □□□□□□□ □□□ □□□□□ □□□ □□□□□□□□ □□□ □□□□ □□□ □□□□ □□□

	[illegible] [illegible]: [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [

□□□□ 9 — □□□□□ □□□ □□□□□ □□□□□ — □□□□□□□□□ 12 □□□ □□□□□ □□□□ □□□□ □□□□

□□ □□□□□□□□□ — □□□□□□□□ □□ □□□□□ □□□□□□□□□ □□□□□□□ □□ □□□-□□□□ □□□□□

□□□□□□ □□□□ □□□□□□□□ □□□□ □□□□□□□□□ '□□ □□□ □□□□ □□□□□□□□□ (□□□□□□□□□ 12) □□□□□□ □□ — □□□□□□□□□□□ □□□□□□□ □□ □□□□□ □□□ □□ □□□□□ □□ □□□□□□□ □□□□□□ □□□□□□ □□ □□□□□ □□□□, □□ □□□□ □□□ □□□□□ □□□□□ □□□ □□□□□□□□ □□□□ □□□ □□□□□□ □□ □□□□□ □□□□, □□ □□□□□□□ □□□□ □□□□ □□□□□ □□□ □□□□□□ □□□□□□□ □□ — □□□□□ □□ □□□□□ □□□ □□□□□ □□□□ □□□□ □□□□□□□□□□□ □□□□□ □□ □□ □□□□□ □□□ □□□ □□ □□□ □□□□□□ □□□□□ □□□□ □□□ □□□

9.1 — COMT-□□□□ □□□□ □□□□□□□ □□□□□□□□□

□□□□□ □□□ □□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□ □□□□□ □□□□□□ □□□ □□□□□□	□□□□□□ — □□□/□□□ □□□□□□□ □□□□□□□□□	□□□ - □□□/□□□ □□□□□ □□□□□□□□□
□□□□ - □□□ □□ □□□□□□□□□□	□□□□ □□□□□□ (120–140+), □□□□ □□□□□□, □□□□□□□ □□□ □□□□□ □□□□□□ □□□□-□□□ □□□ □□□□ □□□□□□ □□□ □□□□, □□□□□□□□□□ □□□□□, □□□□, □□□ □□□ □□□□ □□□□: □□□□□□□□□□□ □□□□□□ □□□ □□□□□ □□□□ □□ "□□□□□□" □□ □□□□ □□□ □□□□ □□□ □□□ □□□ □□□ □□ □□□□□□ □□□	moderate BPM (80–100), □□□ □□□□□□ □□□□□, □□□□ □□□□□□ □□□□□□ □□□□□ □□□□□□□, □□□□, □□□□□□□. □□□□: □□□□□□ □□□□ □□ □□□□□□ □□□ □□ □□□□ □□□□□□□□□□□ □□ □□□□ □□□ □□□ □□□□□□ □□ □□□□□
□□□ / □□□□□	40 Hz □□□□□□□ □□□□ □□□ □□□□ □□□□□□□□□ □□□□□, □□□□□ □□□□□□□□ □□□□ □□ □□□□ □□□□□ □□□□□ □□□□□—□□□□ □□□□ □□□□ □□□ □□□□□□ □□□□□□□□□ □□□□□, □□ □□ □□□ □□□ □□□ □□□ (BPM) '□□ □□□□□	□□□□□ □□□□□□□ □□□□ (8–12 Hz) □□□□□ □□□ □□□□□□□□ □□□ □□□□□□□□□□ □□□□□□□ □□□ □□□□□ □□□□□□□□□□ □□□□□□ □□□ □□□□□ "□ □□□" □□ □□□□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□ □□□
□□□□□□	□□□□□□: □□□□ □□□□□ □□ □□□ □□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□ (BPM) □□□□ □□ □□□□□□ □□□ □□□ □□□□□ □□□□ □□□□□□ □□□ □□ □□□□□ □□□□□□□□ □□ □□□□□□□□□ □□ □□□□□ □□□ □□ □□□ □□□□, □□□□ □□□□□□□□ □□ □□□□ □□□	□□□□□□ (BPM) □□□□□□□ □□□ □□□ □□□□□ □□ □□ □□□ □□□□□□ □□□□ □□□ □□ □□□□□□□ □□□□ □□□□ □□ □□□□ □□□□ □□□□ '□□ □□, □□ □□ □□□□□ □□□ □□□□□ '□□□ □□□□□ □□□□□□ □□□□□□ □□□□ □□, □□ □□□□□ □□□□□□□ □□□□□
□□□□ - □□□□□□□□□□□□	□□□□ □□□ □□□□□□ □□□□ □□□□ □□ 6 □□□ □□□ □□□□, □□□□□□ (BPM) □□□	□□□□□□ □□□□□ □□□ □□□ □□□□□ □□ □□□□□ □□□□ □□ □□□□

	[illegible]-[illegible] [illegible] "[illegible]" [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—[illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 10 — [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible].

[illegible] [illegible] — [illegible]-28: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible]-28 - '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]' - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible], [illegible] [illegible], [illegible] [illegible]'	"[illegible]" [illegible] [illegible] 2-3 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
[illegible] - [illegible] [illegible] [illegible] ([illegible] [illegible])[illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

- [illegible]-[illegible] 3-5 [illegible] [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible], [illegible] [illegible], [illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] OPRM1 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□□ 11 — □□□□□□ □□□□□□□ □□□□□□□□□ — □□□□□□ □□□-□□□□□□□

□□ □□□□□□□□□ — □□□□□□ □□□□ □□□□□□□ □□□ □□□□□□□□□□ □□□□□□□ □□□□ □□, □□□□ □□□ □□□□□□ □□□ □□□ □□□□□□□□ □□□

□□□□□□□□□□ □□□□□□□□□ □□□ "□□□ □□□ □□□ □□□ □□□□ □□□" □□□□ □□□□□□□□ □□□□ □□□ □□□□□□□ □□□, □□□□, □□□□□□ □□□ □□□□□□□ □□□□ □□□□□□ □□□ □□□□□ □□□ □□ □□□□□□□□ □□□ □□□□□□ □□ 25 □□□ □□ □□□ □□□□ □□□□ □□, 35 □□□ □□ □□□ □□□□ □□□□□□ □□□ □□ □□□ □□ □□□□ □□□ □□□□□□□ □□□□□□□□ □□□□ □□□□□, □□ □□□□ □□□□□□□□□□ - □□□□□□□ □□□□ □□□□□□□ □□□□ □□ □□ □□□ □□□ □□□□ □□ - □□□□□ □□□ □□□□□□ □□□□□□□ □□□ □□ □□□□□ □□□□□□□ □□□□

11.1 — □□□□□ □□□□□□□□□ □□□□□

□□ □□ □□□□□□□ □□□ □□ □□ □□□□□ □□ □□ □□□□□□ □□□□□□ □□ □□□□□□□□ □□□□□ □□□□ '□□ □□□□□ □□□ □□ □□□□ □□:

* [□□□□]
* [□□□□]
* [□□□□]

□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□ □□□□ □□□□□ □□ □□□□ □□□ □□□□□, □□□□□ □□□□□□□ □□□ □□□□ (Ulta Lab Tests, Request A Test, LabCorp Direct) □□□□□ □□□□□ □□ □□□□ □□□

□□□□□	□□ □□□ □□□□ □□□□	□□ □□□□□□□ □□ □□□□ □□□	□□□□ □□□□ □□□ □□□□ □□□□ □□□ □□ □□□□ □□□
□□□□ □□□□□□□□□□□	< 8 µmol/L (□□ □□□ □□□□ 6–7)	□□□□□□□□□□ □□□□□□□□ □□□□□ MTHFR □□□□ □□ □□□□□□□□□□□ □□ □□□□ □□□ □□□□□ □□□□	□□□□ □□□□ □□□□ □□: 5-MTHF □□ □□□□ □□□□, TMG/□□□□ □□□□ □□□, B12 □□ □□□□ □□□□□ □□□□ □□□□ □□□□ □□□□ □□ (>15): □□□□□□□□□□ □□□□□ □□ □□□□ □□□ □□□□ □□□
□□□□ □□12 (□□□□□□□□□□□□□□□□□)□	400 pg/mL (□□ □□□ □□□□ > 600)	□□□□ B12 □□ □□□□ □□ □□□□□ □□□□ □□ □□ □□□□□ □□□□□□□□□□□ □□ □□□□□□□□□□ □□□ □□□ □□□ □□□□□□ □□ □□□□ □□□	□□□□ □□□□ □□□□□ □□□ □□ □□□□□ □□ □□□ □□: □□□□□□□□□ □□□□ '□□ □□□ (□□□□□□ □□□□ □□□ □□□)□ □□□ □□ □□□□□□□□ □□□ □□□ □□□□ □□□□ □□□□ □□□□□ □□□□ □□ (>2000): □□□□□ □□□□□
□□□□ □□□□□□□□□□ (□□□□□□□□□ □□□□□□□□□□ □□□□)□	RBC Mg: 5.2–6.5 mg/dL	□□□□□□□□□□ □□ □□□□□□□□ □□□□□ □□□□ □□□□	□□ □□□ □□: □□□□□□□□□□ □□□□□□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□ □□□ □□□ □□

		□□□□□□□□□□□ □□ □□□□□ □□□□□ □□□□□□□□□□□ □□□□□ □□□□□□—□□□.□□.□□. (RBC) □□□□□ □□□□□□□□□□□ □□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□	□□□□□□□ (□□□□□□ □□ □□□□□□□ □□□□□□, □□□□□□□ □□□□□□, □□□□□□□ □□□□□□□□□, □□□□□) □□ □□□□□ □□□□□
□□□□□ □□□□□□□□ □□ (25-OH-D).	50–80 ng/mL (□□□□□□□ □□□□□ □□ □□ □□□□ □□□□□)□	□□□□□□□□ □□ □□ □□□□□ - □□ □□□□□□□□□ □□ □□□□□□□□□ (BH4 □□□□□□□□□□), □□□□□□ □□□□□□ □□□□ □□□□ □□ □□□□□□□□□ □□□□	□□□□□ □□□□ 40 □□□□ □□□□ □□□□ □□: □□□□ □□3 (D3) □□ □□□□□ □□□□□□ □□□□ □□□□ □□□□□, □□□□ □□□□□ □□□□ □□2 (K2) □□ □□□□ □□□□□ □□□□ 20 □□□□ □□□□ □□□□ □□: □□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□□□□
HS-CRP (□□□□-□□□□□□□□□□□ □□-□□□□□□□□ □□□□□□□□).	< 1.0 mg/L	□□□□□□□□ □□□□□□□□□□□ □□ □□□□□□ □□□□□□□□□□□□□□□ □□ □□□□, □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□ □□□□□ □□□□ □□□□ CRP □□□□ □□□□□□ □□□□□□□□□□□□ □□□□□□□□□ □□□□ □□□□□□□□□ □□□□	□□□□□ □□□□□ □□□□□ □□: □□□□□□-3 □□ □□□□□□ □□ □□□□□□□ □□□□ (EPA □□□□□), □□□□□ □□ □□□□□□□□ □□ □□□□□□□ □□□□, □□□□□□□□□ □□□□□ □□□□□ □□ □□□□□ □□ □□□□□□□ □□□□, □□□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□□ □□□□□ □□ □□□□ □□□□□□□□ □□□□□□ □□□□□
□□□□□□□□ □□□□□□□□ □□□□ □□□□□□□□□	□□□□□□□□ □□□□□□□□: 5 µIU/mL □□□□ □□□□; □□□□□□□□ □□□□□□□□: 70–85 mg/dL.	□□□□□□□□□□ □□□□□ □□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□□□□□□, □□□□, □□□□□ □□□□ □□□□□ □□□□□□□□ □□□□ □□□□□□□□□ □□□□□ □□□	□□ □□□□□□□□ □□ □□□□□ □□□□□ □□ □□ □□□□□□□□ □□ □□ (□□□□□□□□ □□□□ □□ □□□□□□□□□): □□□□□□ □□□□□ □□□□□□ □□□□ (□□□□□□□□ □□□□□□□□□□□□□□□ □□□□□, □□□□□□□□□□ □□□□□□□□□ □□□□□□ □□□□)□ □□ □□□□□□□□ □□ □□□□□ □□□□□ □□: □□□□□□ □□□□ □□□□□ □□□□□
□□□□□□□□□□□□□ (□□□□□ □□□□ □□□□□□) - □□□□□□ □□□□□□	□□ □□□□□ □□□□□ □□□□ □□□□ □□ □□□□□□□ □□□□□□ □□ — □□□□ □□ □□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□□ □□□□□	□□□□□□□□□ □□□□□□ □□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□□□□□□□□□□ □□□□□ □□□□□□□□□, □□□□□□ □□□□ □□□□ □□□□□□□□ □□ □□□□□ □□ - □□ □□ □□□□□ □□□□ □□ □□□□□□□	□□□□□ □□□□□ □□□□□ □□□□ □□: □□□□□□ □□□□ □□□□□ □□□□□ □□□□□□ □□ □□□□□□□□ □□□□ □□□□□□ □□□□□□□□□ רון □□ □□□□□□ □□ □□□□— □□□□□□ □□□□□□□□□רון □□ □□□□□ HPG □□□□□□ □□□□□ □□□□□□ □□□□ □□ □□□□□ □□, □□□□□□ □□□□□□ □□□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□□

		[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	

11.2 — [illegible] [illegible]-[illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

	[illegible] [illegible] [illegible] [illegible]

11.3 — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

- [illegible] 12 [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] (Hallmarks, [illegible], [illegible] [illegible]): [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]-[illegible] [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] "[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□ □□□: biohacker_multi_domain_profiler.py | biohacker_final_edition_with_json_import.html | peptide_advisor_with_oral_health.html

□□□□ □□□□□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□□□□□□□□□ □□□□□□□□□ □□□ □□□□□□□□□ □□□ □□□ □□□ □□ □□□□□□□ □□□□□□□ □□□□ □□□

□□ □□□□ □□□□ □□□□□□□ □□ □□□□□□□ □□□□ □□□□ □□□ □□□□□□□□ □□□□□□□□ □□, □□□ □□□□□□ □□□ □□□□ □□□□□

□□□□ □□□ □□□ □□□ / □□□□□□□ □□□□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□